Urologix (ULGX) 0.1600 $ULGX
Urologix to Host Its Fiscal Year 2014 Third Quarter Conference Call
GlobeNewswire - Wed Apr 30, 4:01PM CDT
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present fiscal year 2014 third quarter results on Tuesday, May 6, 2014 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1--866-515-2911 and enter the Participant Passcode 73790575 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
Global Ablation Technologies Market 2012-2016: Major Cancer Diseases that Use Ablation Technology Devices are Discussed in Detail
M2 - Mon Mar 10, 11:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5z78kx/global_ablation) has announced the addition of the "Global Ablation Technologies Market 2012-2016" report to their offering. The analysts forecast the Global Ablation Technologies market to grow at a CAGR of 10.52 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased demand for minimally invasive surgical procedures. The Global Ablation Technologies market has also been witnessing the trend of miniaturizing medical devices. However, the varying regulations for medical devices could pose a challenge to the growth of this market. Ablation technology devices are used for various clinical applications and Cancer therapy, and accounted for the largest segment of the Global Ablation Technologies market. The key vendors dominating this market space include Boston Scientific Corp., Medtronic Inc., St.Jude Medical Inc., and Varian Medical Systems Inc. The other vendors mentioned in the report are Accuray Inc., Alcon Laboratories Inc., AngioDynamics Inc., Arthrocare Corp., Atricure Inc., ATS Medical Inc., Biosense Webster Inc., BSD Medical Corporation, C.R. Bard Inc., Candela Corp., CardioGenesis Corp., CermaVEIN SAS, ConMed Corporation, Covidien plc, EDAP TMS S.A., Elekta AB, Endo Health Solutions Inc., Galil Medical Ltd., HealthTronics Inc., Hologic Inc., Idoman Ltd., Maquet Holding GmbH and Co. KG (Gentinge AB group), Microsulis Medical Ltd, Misonix Inc., nContact Surgical Inc., Olympus Corp., Relievant Medsystems, Rhythmia Medical Inc., Smith and Nephew plc, Solta Medical Inc., Syneron Medical Ltd., TheraGenics Corp., Urologix Inc., VNUS Medical Technologies Inc., and Zeltiq Aesthetics Inc. Commenting on the report, an analyst from the Healthcare team said: One of the upcoming trends in the Global Ablation Technology market is the rapid advancements in technology using ablation technology devices. Although the market for ablation technology devices is at a mature stage, the level of technology is still at a nascent stage; more devices with cutting-edge technology are expected to be introduced in the near future. Recently, laser ablation devices have been introduced to perform precise ablation of body tissue; these devices run on a laser energy transmission mechanism using fiber optics. This kind of device is used in transmyocardial revascularization and angioplasty. Another major advancement is the usage of catheter ablation for atrial fibrillation, which is commonly used to control tachy-arrhythmia. Thus, the rapid advancement in technology is an emerging trend that has a strong impact on the market. For more information visit http://www.researchandmarkets.com/research/5z...l_ablation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Urologix Secures Extension of Credit Facility
GlobeNewswire - Tue Feb 04, 9:49PM CST
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced that it has secured an extension to June 30, 2014 of its credit facility with Silicon Valley Bank ("SVB"
, the commercial banking division of SVB Financial Group. The line of credit with SVB allows borrowing by the Company of up to the lesser of $2.0 million or the defined borrowing base consisting of 80% of eligible accounts receivable.
Urologix Reports Fiscal Year 2014 Second Quarter Results
GlobeNewswire - Tue Feb 04, 9:49PM CST
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal second quarter ended December 31, 2013.
Urologix Applauds Research on Cost of BPH to Healthcare System
GlobeNewswire - Mon Aug 26, 7:04AM CDT
via PRWEB - Urologix, Inc. (OTC:ULGX) applauds the recent clinical article by Dr. Khurshid Roghmann et al, "Incidence and treatment patterns in males presenting with lower urinary tract symptoms to the emergency department in the United States" published in the June, 2013 Journal of Urology. The study examines the growing incidence and costs of emergency room admissions for men with BPH. Previous studies have looked at increases in co-morbidities associated with BPH hospital admissions, but this is the first to examine unrecognized costs of BPH capturing treatment costs for both the ER and hospital admissions. An abstract of the article can be found at http://www.urologix.com/clinicians/cooled-the...ations.php or http://www.urologix.com/clinicians/prostiva-r...ations.php on the Urologix website.
Delisting of Securities of SmartHeat Inc., Ampal-American Israel Corporation, PURE Bioscience, Inc., Urologix, Inc. and Strategic Diagnostics Inc. From The NASDAQ Stock Market
GlobeNewswire - Mon Aug 19, 3:05PM CDT
The NASDAQ Stock Market announced today that it will delist the common stock of SmartHeat Inc. SmartHeat Inc.'s stock was suspended on November 09, 2012 and has not traded on NASDAQ since that time.
Urologix to Host Its Fourth Quarter and Full Fiscal Year 2013 Conference Call
GlobeNewswire - Wed Aug 14, 4:00PM CDT
Urologix(R), Inc. (OTC:ULGX) will host a conference call to present fourth quarter and full fiscal year 2013 results on Tuesday, August 20, 2013 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-877-703-6103 and enter the Participant Passcode 11902670 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
Urologix Announces Restructuring of Payment Obligations to Medtronic and Reports Preliminary Fiscal Year 2013 Revenue and Cash Results
GlobeNewswire - Mon Jul 01, 8:00AM CDT
Urologix(R), Inc. (OTCQB:ULGX), the leading provider of in-office BPH therapy, announces the restructuring of payment obligations to Medtronic related to the licensing agreement with Medtronic for the Prostiva(R) Radio Frequency (RF) Therapy System and reports preliminary revenue and cash results for its fourth quarter and fiscal year 2013 ended June 30, 2013.
The Global Ablation Devices Market was Valued at $7.5 Billion in 2011 and is Poised to Grow at a CAGR of 10.5% to Reach $12.4 Billion by 2016
M2 - Thu Jun 27, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl2q25/ablation_devices) has announced the addition of the "Ablation Devices Market to 2016 - Global Market Forecast and Trends Analysis by Technology, Devices & Applications" report to their offering. Ablation procedures have witnessed significant growth in the recent years, which are attributable to factors such as growing healthcare expenditure, favorable demographics and cost effectiveness over tradition surgical procedures. Moreover, increasing applications in cancer and cardiac segment are fueling the market growth. Radiation therapy accounted for the largest share of 41% of the total ablation technologies market in 2011. The major driver of radiation therapy is the fact that it is applicable to any form of cancer ranging from soft tissue such as liver, lungs to bone metastases. Compared to most other techniques, radiation therapy is considered to be effective in all cancer scenarios, thus it is a single treatment for control of cancer
Global Ablation Technologies Market Report 2012-2016: Boston Scientific, Medtronic, St Jude Medical and Varian Medical Dominate the Industry
M2 - Tue Jun 11, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gf85bm/global_ablation) has announced the addition of the "Global Ablation Technologies Market 2012-2016" report to their offering. Global Ablation Technologies market to grow at a CAGR of 10.52 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased demand for minimally invasive surgical procedures. The Global Ablation Technologies market has also been witnessing the trend of miniaturizing medical devices. However, the varying regulations for medical devices could pose a challenge to the growth of this market. Global Ablation Technologies market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Global Ablation Technologies market in the Americas, the EMEA, and the APAC regions; it also covers the Global Ablation Technologies market by segmentation. The market landscape of the Global Thermal Ablation Technologies mar
Medtronic, Inc. Market Share Analysis Report
M2 - Mon Jun 10, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jm64rr/medtronic_inc) has announced the addition of the "Medtronic, Inc. Market Share Analysis" company profile to their offering. This report provides in-depth information on Medtronic, Inc.'s market position in the different medical equipment markets it operates in. The report provides Medtronic, Inc. market share information in 17 key market categories: - Neurostimulation Devices - Cardiac Rhythm Management - Spinal Surgery - CSF Management - Prosthetic Heart Valves - Cardiovascular Surgery - Remote Patient Monitoring - Orthobiologics - Neurosurgical Products - External Defibrillators - Insulin Delivery - Interventional Cardiology - Peripheral Vascular Devices - Cardiovascular Prosthetic Devices - Electrophysiology - Infusion Systems - Glucose Monitoring. The report also provides data and information on the overall competitive landscape of the markets, the company operates in. The report is supplemented with global corporate-level profil
KRO, ULGX, RMBS, IVE, ANTP, BXC Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Jun 07, 6:14AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Kronos Worldwide Inc (NYSE:KRO), Urologix Inc (NASDAQ:ULGX), Rambus Inc (NASDAQ:RMBS), iShares S&P 500 Value Index Fund (NYSE:IVE), Phazar Corp (NASDAQ:ANTP), Bluelinx Holdings Inc (NYSE:BXC) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Urologix Inc to list common stock in the OTCQB Marketplace
M2 - Thu Jun 06, 6:56AM CDT
The board of directors of Urologix Inc (NasdaqCM:ULGX), a provider of invasive medical products, reported on Wednesday that it has approved the transfer of its common stock from The NASDAQ Capital Market to OTC Markets Group's OTCQB Marketplace (OTCQB).
Urologix to Transfer From NASDAQ to the OTCQB Marketplace
GlobeNewswire - Wed Jun 05, 3:00PM CDT
Urologix(R), Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that its Board of Directors has authorized the transfer of the Company's common stock from The NASDAQ Capital Market ("NASDAQ" to OTC Markets Group's OTCQB Marketplace ("OTCQB" . Urologix expects that its stock will begin trading on the OTCQB under the ticker symbol "ULGX" effective June 7, 2013. As of that date, investors and other interested parties will be able to view Real Time Level II stock quotes at http://www.otcmarkets.com/stock/ULGX/quote. The OTCQB marketplace includes more than 3,100 securities representing U.S. companies that are current in their reporting requirements with the Securities and Exchange Commission or U.S. banking regulators.
Urologix Reports Fiscal Year 2013 Third Quarter Results and Reaffirms Annual Guidance
GlobeNewswire - Wed May 01, 3:00PM CDT
Third Quarter Summary
ULGX, CWT, DBLE, BMR, POL, EQY Expected To Be Down After Next Earnings Releases
M2 - Tue Apr 30, 5:59AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Wednesday, May 1st 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports. Urologix Inc (NASDAQ:ULGX), CALIFORNIA WATER SERVICE GROUP (NYSE:CWT), Double Eagle Petroleum Co (NASDAQ
BLE), BioMed Realty Trust Inc (NYSE:BMR), PolyOne Corp (NYSE
OL), EQUITY ONE, INC. (NYSE:EQY) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific tech
SPN, ANH, HXM, AVID, ULGX, MCRS Expected To Be Down After Next Earnings Releases
M2 - Wed Apr 24, 6:02AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, April 25th 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and June earnings reports. Superior Energy Services Inc (NYSE:SPN), Anworth Mortgage Asset Corp (NYSE:ANH), Desarrolladora Homex SAB de CV (NYSE:HXM), Avid Technology Inc (NASDAQ:AVID), Urologix Inc (NASDAQ:ULGX), MICROS Systems Inc (NASDAQ:MCRS) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released.
VIG, DRAD, ULGX, TRMB, NICK, WAT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Apr 23, 8:55AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Vanguard Dividend Appreciation ETF (NYSE:VIG), Digirad Corp (NASDAQ RAD), Urologix Inc (NASDAQ:ULGX), Trimble Navigation Ltd (NASDAQ:TRMB), Nicholas Financial Inc (NASDAQ:NICK), Waters Corp (NYSE:WAT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Urologix Receives Extension From NASDAQ to Regain Compliance With Listing Requirements
GlobeNewswire - Wed Apr 17, 4:00PM CDT
Urologix(R), Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that the NASDAQ Hearings Panel (the "Panel" of The NASDAQ Stock Market LLC ("NASDAQ" has granted the Company's request for a further extension to regain compliance with the listing requirements of the NASDAQ.
Urologix to Host Its Fiscal Year 2014 Third Quarter Conference Call
GlobeNewswire - Wed Apr 30, 4:01PM CDT
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present fiscal year 2014 third quarter results on Tuesday, May 6, 2014 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1--866-515-2911 and enter the Participant Passcode 73790575 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
Global Ablation Technologies Market 2012-2016: Major Cancer Diseases that Use Ablation Technology Devices are Discussed in Detail
M2 - Mon Mar 10, 11:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5z78kx/global_ablation) has announced the addition of the "Global Ablation Technologies Market 2012-2016" report to their offering. The analysts forecast the Global Ablation Technologies market to grow at a CAGR of 10.52 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased demand for minimally invasive surgical procedures. The Global Ablation Technologies market has also been witnessing the trend of miniaturizing medical devices. However, the varying regulations for medical devices could pose a challenge to the growth of this market. Ablation technology devices are used for various clinical applications and Cancer therapy, and accounted for the largest segment of the Global Ablation Technologies market. The key vendors dominating this market space include Boston Scientific Corp., Medtronic Inc., St.Jude Medical Inc., and Varian Medical Systems Inc. The other vendors mentioned in the report are Accuray Inc., Alcon Laboratories Inc., AngioDynamics Inc., Arthrocare Corp., Atricure Inc., ATS Medical Inc., Biosense Webster Inc., BSD Medical Corporation, C.R. Bard Inc., Candela Corp., CardioGenesis Corp., CermaVEIN SAS, ConMed Corporation, Covidien plc, EDAP TMS S.A., Elekta AB, Endo Health Solutions Inc., Galil Medical Ltd., HealthTronics Inc., Hologic Inc., Idoman Ltd., Maquet Holding GmbH and Co. KG (Gentinge AB group), Microsulis Medical Ltd, Misonix Inc., nContact Surgical Inc., Olympus Corp., Relievant Medsystems, Rhythmia Medical Inc., Smith and Nephew plc, Solta Medical Inc., Syneron Medical Ltd., TheraGenics Corp., Urologix Inc., VNUS Medical Technologies Inc., and Zeltiq Aesthetics Inc. Commenting on the report, an analyst from the Healthcare team said: One of the upcoming trends in the Global Ablation Technology market is the rapid advancements in technology using ablation technology devices. Although the market for ablation technology devices is at a mature stage, the level of technology is still at a nascent stage; more devices with cutting-edge technology are expected to be introduced in the near future. Recently, laser ablation devices have been introduced to perform precise ablation of body tissue; these devices run on a laser energy transmission mechanism using fiber optics. This kind of device is used in transmyocardial revascularization and angioplasty. Another major advancement is the usage of catheter ablation for atrial fibrillation, which is commonly used to control tachy-arrhythmia. Thus, the rapid advancement in technology is an emerging trend that has a strong impact on the market. For more information visit http://www.researchandmarkets.com/research/5z...l_ablation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Urologix Secures Extension of Credit Facility
GlobeNewswire - Tue Feb 04, 9:49PM CST
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced that it has secured an extension to June 30, 2014 of its credit facility with Silicon Valley Bank ("SVB"
, the commercial banking division of SVB Financial Group. The line of credit with SVB allows borrowing by the Company of up to the lesser of $2.0 million or the defined borrowing base consisting of 80% of eligible accounts receivable. Urologix Reports Fiscal Year 2014 Second Quarter Results
GlobeNewswire - Tue Feb 04, 9:49PM CST
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal second quarter ended December 31, 2013.
Urologix Applauds Research on Cost of BPH to Healthcare System
GlobeNewswire - Mon Aug 26, 7:04AM CDT
via PRWEB - Urologix, Inc. (OTC:ULGX) applauds the recent clinical article by Dr. Khurshid Roghmann et al, "Incidence and treatment patterns in males presenting with lower urinary tract symptoms to the emergency department in the United States" published in the June, 2013 Journal of Urology. The study examines the growing incidence and costs of emergency room admissions for men with BPH. Previous studies have looked at increases in co-morbidities associated with BPH hospital admissions, but this is the first to examine unrecognized costs of BPH capturing treatment costs for both the ER and hospital admissions. An abstract of the article can be found at http://www.urologix.com/clinicians/cooled-the...ations.php or http://www.urologix.com/clinicians/prostiva-r...ations.php on the Urologix website.
Delisting of Securities of SmartHeat Inc., Ampal-American Israel Corporation, PURE Bioscience, Inc., Urologix, Inc. and Strategic Diagnostics Inc. From The NASDAQ Stock Market
GlobeNewswire - Mon Aug 19, 3:05PM CDT
The NASDAQ Stock Market announced today that it will delist the common stock of SmartHeat Inc. SmartHeat Inc.'s stock was suspended on November 09, 2012 and has not traded on NASDAQ since that time.
Urologix to Host Its Fourth Quarter and Full Fiscal Year 2013 Conference Call
GlobeNewswire - Wed Aug 14, 4:00PM CDT
Urologix(R), Inc. (OTC:ULGX) will host a conference call to present fourth quarter and full fiscal year 2013 results on Tuesday, August 20, 2013 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-877-703-6103 and enter the Participant Passcode 11902670 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
Urologix Announces Restructuring of Payment Obligations to Medtronic and Reports Preliminary Fiscal Year 2013 Revenue and Cash Results
GlobeNewswire - Mon Jul 01, 8:00AM CDT
Urologix(R), Inc. (OTCQB:ULGX), the leading provider of in-office BPH therapy, announces the restructuring of payment obligations to Medtronic related to the licensing agreement with Medtronic for the Prostiva(R) Radio Frequency (RF) Therapy System and reports preliminary revenue and cash results for its fourth quarter and fiscal year 2013 ended June 30, 2013.
The Global Ablation Devices Market was Valued at $7.5 Billion in 2011 and is Poised to Grow at a CAGR of 10.5% to Reach $12.4 Billion by 2016
M2 - Thu Jun 27, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl2q25/ablation_devices) has announced the addition of the "Ablation Devices Market to 2016 - Global Market Forecast and Trends Analysis by Technology, Devices & Applications" report to their offering. Ablation procedures have witnessed significant growth in the recent years, which are attributable to factors such as growing healthcare expenditure, favorable demographics and cost effectiveness over tradition surgical procedures. Moreover, increasing applications in cancer and cardiac segment are fueling the market growth. Radiation therapy accounted for the largest share of 41% of the total ablation technologies market in 2011. The major driver of radiation therapy is the fact that it is applicable to any form of cancer ranging from soft tissue such as liver, lungs to bone metastases. Compared to most other techniques, radiation therapy is considered to be effective in all cancer scenarios, thus it is a single treatment for control of cancer
Global Ablation Technologies Market Report 2012-2016: Boston Scientific, Medtronic, St Jude Medical and Varian Medical Dominate the Industry
M2 - Tue Jun 11, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gf85bm/global_ablation) has announced the addition of the "Global Ablation Technologies Market 2012-2016" report to their offering. Global Ablation Technologies market to grow at a CAGR of 10.52 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased demand for minimally invasive surgical procedures. The Global Ablation Technologies market has also been witnessing the trend of miniaturizing medical devices. However, the varying regulations for medical devices could pose a challenge to the growth of this market. Global Ablation Technologies market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Global Ablation Technologies market in the Americas, the EMEA, and the APAC regions; it also covers the Global Ablation Technologies market by segmentation. The market landscape of the Global Thermal Ablation Technologies mar
Medtronic, Inc. Market Share Analysis Report
M2 - Mon Jun 10, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jm64rr/medtronic_inc) has announced the addition of the "Medtronic, Inc. Market Share Analysis" company profile to their offering. This report provides in-depth information on Medtronic, Inc.'s market position in the different medical equipment markets it operates in. The report provides Medtronic, Inc. market share information in 17 key market categories: - Neurostimulation Devices - Cardiac Rhythm Management - Spinal Surgery - CSF Management - Prosthetic Heart Valves - Cardiovascular Surgery - Remote Patient Monitoring - Orthobiologics - Neurosurgical Products - External Defibrillators - Insulin Delivery - Interventional Cardiology - Peripheral Vascular Devices - Cardiovascular Prosthetic Devices - Electrophysiology - Infusion Systems - Glucose Monitoring. The report also provides data and information on the overall competitive landscape of the markets, the company operates in. The report is supplemented with global corporate-level profil
KRO, ULGX, RMBS, IVE, ANTP, BXC Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Jun 07, 6:14AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Kronos Worldwide Inc (NYSE:KRO), Urologix Inc (NASDAQ:ULGX), Rambus Inc (NASDAQ:RMBS), iShares S&P 500 Value Index Fund (NYSE:IVE), Phazar Corp (NASDAQ:ANTP), Bluelinx Holdings Inc (NYSE:BXC) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Urologix Inc to list common stock in the OTCQB Marketplace
M2 - Thu Jun 06, 6:56AM CDT
The board of directors of Urologix Inc (NasdaqCM:ULGX), a provider of invasive medical products, reported on Wednesday that it has approved the transfer of its common stock from The NASDAQ Capital Market to OTC Markets Group's OTCQB Marketplace (OTCQB).
Urologix to Transfer From NASDAQ to the OTCQB Marketplace
GlobeNewswire - Wed Jun 05, 3:00PM CDT
Urologix(R), Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that its Board of Directors has authorized the transfer of the Company's common stock from The NASDAQ Capital Market ("NASDAQ"
to OTC Markets Group's OTCQB Marketplace ("OTCQB" . Urologix expects that its stock will begin trading on the OTCQB under the ticker symbol "ULGX" effective June 7, 2013. As of that date, investors and other interested parties will be able to view Real Time Level II stock quotes at http://www.otcmarkets.com/stock/ULGX/quote. The OTCQB marketplace includes more than 3,100 securities representing U.S. companies that are current in their reporting requirements with the Securities and Exchange Commission or U.S. banking regulators. Urologix Reports Fiscal Year 2013 Third Quarter Results and Reaffirms Annual Guidance
GlobeNewswire - Wed May 01, 3:00PM CDT
Third Quarter Summary
ULGX, CWT, DBLE, BMR, POL, EQY Expected To Be Down After Next Earnings Releases
M2 - Tue Apr 30, 5:59AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Wednesday, May 1st 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports. Urologix Inc (NASDAQ:ULGX), CALIFORNIA WATER SERVICE GROUP (NYSE:CWT), Double Eagle Petroleum Co (NASDAQ
BLE), BioMed Realty Trust Inc (NYSE:BMR), PolyOne Corp (NYSE OL), EQUITY ONE, INC. (NYSE:EQY) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific tech SPN, ANH, HXM, AVID, ULGX, MCRS Expected To Be Down After Next Earnings Releases
M2 - Wed Apr 24, 6:02AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, April 25th 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and June earnings reports. Superior Energy Services Inc (NYSE:SPN), Anworth Mortgage Asset Corp (NYSE:ANH), Desarrolladora Homex SAB de CV (NYSE:HXM), Avid Technology Inc (NASDAQ:AVID), Urologix Inc (NASDAQ:ULGX), MICROS Systems Inc (NASDAQ:MCRS) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released.
VIG, DRAD, ULGX, TRMB, NICK, WAT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Apr 23, 8:55AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Vanguard Dividend Appreciation ETF (NYSE:VIG), Digirad Corp (NASDAQ
RAD), Urologix Inc (NASDAQ:ULGX), Trimble Navigation Ltd (NASDAQ:TRMB), Nicholas Financial Inc (NASDAQ:NICK), Waters Corp (NYSE:WAT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: Urologix Receives Extension From NASDAQ to Regain Compliance With Listing Requirements
GlobeNewswire - Wed Apr 17, 4:00PM CDT
Urologix(R), Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that the NASDAQ Hearings Panel (the "Panel"
of The NASDAQ Stock Market LLC ("NASDAQ" has granted the Company's request for a further extension to regain compliance with the listing requirements of the NASDAQ. 
